Loading...
•
Mar 31, 2022
Kala Bio Q1 2022 Earnings Report
Kala reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
Kala Pharmaceuticals reported net product revenues of $1.4 million for the quarter ended March 31, 2022, with $1.0 million from EYSUVIS sales and $0.4 million from INVELTYS sales. The company's cash, cash equivalents, and short-term investments were $70.2 million as of March 31, 2022.
EYSUVIS prescription growth was 18% in 1Q 2022.
Expanded coverage for EYSUVIS to 92% of total commercial lives and 30% of all Medicare lives.
Presented KPI-012 Phase 1b clinical data at ARVO.
Initiation of Phase 2/3 clinical trial in PCED expected 4Q 2022.
Forward Guidance
Kala anticipates that its cash resources as of March 31, 2022, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...